Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.
PRA Health Boosts Health Harmony COVID-19 Monitoring Program
by Zacks Equity Research
PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.
Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management
by Zacks Equity Research
Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.
Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS
by Zacks Equity Research
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now
by Zacks Equity Research
Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.
Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA
by Zacks Equity Research
Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.
Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon
by Zacks Equity Research
Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.
DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe
by Zacks Equity Research
DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Medtronic's StealthStation Feature Recall Classified Class I
by Zacks Equity Research
This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.
Globus Medical Faces Business Loss Amid Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.
Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
Investor confidence is high in LHC Group (LHCG), thanks to solid prospects
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.
Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy
by Zacks Equity Research
Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.
IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test
by Zacks Equity Research
This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.
Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns
by Zacks Equity Research
The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.
Here's Why You Should Hold on to Haemonetics Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.
ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP
by Zacks Equity Research
This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.
Here's Why You Should Retain NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and solid recurring revenue base.
Ecolab's AdvaCare Disinfectant Receives First EPA Approval
by Zacks Equity Research
Ecolab's (ECL) AdvaCare Disinfectant receives first EPA approval for a laundry disinfectant and oxidizer emerging viral pathogen claim that is effective against the coronavirus.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.
Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply
by Zacks Equity Research
Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.